STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.

Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.

This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.

All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at the 2024 Leerink Partners Healthcare Crossroads Conference.

The presentation is scheduled for May 29, 2024, at 8:40 a.m. CDT. Interested parties can access a live webcast of the presentation on Bio-Techne's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) and Regulus Therapeutics Inc. announced positive top-line results from the second cohort of their Phase 1b MAD study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The collaboration, ongoing since 2020, utilizes Bio-Techne's Simple Western™ platforms and ExosomeDx CLIA laboratory for biomarker analysis. Regulus developed assays to measure polycystin 1 and 2 levels, key biomarkers in ADPKD, using Bio-Techne’s technology. This milestone highlights the clinical potential of RGLS8429 and advances the study, aiming to improve global healthcare with innovative therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary

Molecular Instruments announced a significant legal victory with the Patents Court of the High Court of England and Wales ruling in their favor against Advanced Cell Diagnostics, a Bio-Techne group company (NASDAQ: TECH). The court revoked two European patents (UK) held by Advanced Cell Diagnostics and dismissed their infringement claims against Molecular Instruments regarding the HCR™ RNA-ISH technology. This action resulted in Advanced Cell Diagnostics being ordered to pay £1.35 million (approximately $1.72 million) to Molecular Instruments. The judgment by Mr. Justice Meade, delivered on April 23, 2024, concluded that the patents were invalid due to obviousness based on overwhelming primary evidence. Dr. Harry Choi, CEO of Molecular Instruments, expressed satisfaction with the outcome, emphasizing their commitment to supporting UK researchers with advanced molecular tools.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has confirmed that Kim Kelderman, President and CEO, will present at the BofA Securities Health Care Conference on May 14, 2024. The presentation will be available via live webcast on the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, showcasing its cell and gene therapy workflow solutions. The event will feature speaker sessions, poster presentations, and a multimedia experience highlighting Bio-Techne's innovative tools and solutions for advancing cell and gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) reported third-quarter fiscal 2024 results with organic revenue up 2%, GAAP EPS at $0.31, adjusted EPS at $0.48, and strong commercial execution in Diagnostics & Genomics segment. Cash flow increased by 31% to $223.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
News
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended March 31, 2024. The dividend will be payable on May 24, 2024, to common shareholders of record on May 13, 2024. The company is a global life sciences provider of tools and bioactive reagents for research and clinical diagnostics, generating $1.1 billion in net sales in fiscal 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
dividends
-
Rhea-AI Summary

Bio-Techne appointed Dr. Judith Klimovsky as an independent director on the Board of Directors, bringing valuable experience from the biotechnology industry. Dr. Klimovsky's background in antibody therapeutics and global clinical development positions her well to contribute to Bio-Techne's expansion efforts. The addition of Dr. Klimovsky enhances the board's expertise and diversity, with a focus on Latin America and global biopharma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
management
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced a new distribution agreement with Thermo Fisher Scientific, effective May 1, 2024. This strategic partnership will see Thermo Fisher distributing Bio-Techne's innovative products across Europe, enhancing support for researchers and accelerating scientific discoveries. The collaboration aims to empower scientists in areas such as cell and gene therapy, immunology, and neuroscience, ultimately advancing healthcare outcomes. Thermo Fisher's dedication to fostering innovation and collaboration within the scientific community is highlighted through this partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) and Novomol-Dx have developed the Bio-Marker Pathfinder (BMP), a groundbreaking ocular biomarker kit for point-of-care application. The kit, running on Bio-Techne's Ella™ platform, provides accurate, reliable data in less than 90 minutes, targeting Dry Eye Disease, Diabetic Retinopathy, and patient monitoring post-ocular surgeries. With potential applications beyond ocular diseases, the BMP kit addresses a significant unmet need in India, aiming to benefit millions of patients. The partnership between Bio-Techne and Novomol-Dx showcases the potential of biomarker research in diagnostic and prognostic applications, promising a brighter future for ocular healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

7.60B
156.43M
1.05%
101.12%
3.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MINNEAPOLIS